International Stem Cell Corporation (ISCO), headquartered in the United States, is a pioneering entity in the biotechnology industry, specialising in stem cell research and regenerative medicine. Founded in 2007, ISCO has made significant strides in developing innovative therapies and products, particularly in the fields of cell therapy and human therapeutic applications. The company is renowned for its unique human parthenogenetic stem cell technology, which offers a promising alternative to traditional stem cell sources. ISCO's core products include stem cell lines and related research tools, which are designed to advance scientific understanding and therapeutic potential. With a strong market position, ISCO has achieved notable milestones, including collaborations with leading research institutions and advancements in clinical applications, solidifying its reputation as a leader in the stem cell sector.
How does International Stem Cell Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
International Stem Cell Corporation's score of 26 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, International Stem Cell Corporation (ISCC) reported total carbon emissions of approximately 2,585,100 kg CO2e across all scopes. This includes 2,585,100 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and an equal amount from Scope 2 emissions, which are indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, Scope 3 emissions were also reported at 2,585,100 kg CO2e, with significant contributions from business travel, amounting to 657,630 kg CO2e. Despite the comprehensive emissions reporting, ISCC has not established specific reduction targets or climate pledges, indicating a potential area for future commitment. The absence of cascading data from a parent company suggests that ISCC operates independently in its emissions reporting and climate strategy. Overall, while ISCC has provided detailed emissions data, the lack of defined reduction initiatives highlights an opportunity for the corporation to enhance its climate commitments and align with industry standards for sustainability.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 2,585,100 |
| Scope 2 | 2,585,100 |
| Scope 3 | 2,585,100 |
A significant portion of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 33% of total emissions under the GHG Protocol, with "Business Travel" being the primary emissions source at 25% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
International Stem Cell Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

